Clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease

Clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease

Aim. To investigate the clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease (CHD). Subjects and methods. Fifty patients aged 40-75 years with asthma concurrent with CHD were examined. External respiratory function (ERF),...

Full description

Bibliographic Details
Main Authors:	O V Byelan, O A Borzykh, T V Mamontova, I P Kaidashev
Format:	Article
Language:	Russian
Published:	"Consilium Medicum" Publishing house 2015-09-01
Series:	Терапевтический архив
Subjects:	asthma coronary heart disease pioglitazone systemic inflammation endothelial dysfunction
Online Access:	https://ter-arkhiv.ru/0040-3660/article/view/31806

Similar Items

The features of risk factors, systemic inflammation, and endothelial dysfunction in patients with asthma concurrent with coronary heart disease
by: O V Belan, et al.
Published: (2014-03-01)

Endothelial dysfunction and its correction with perindopril therapy in patients with coronary heart disease
by: O. A. Vartanova, et al.
Published: (2008-06-01)

Physical rehabilitation and endothelial dysfunction in coronary heart disease
by: V. A. Margazin, et al.
Published: (2006-02-01)

THE INFLUENCE OF CORONARY BYPASS ON ENDOTHELIAL AND ERECTILE DYSFUNCTION IN ISCHEMIC HEART DISEASE
by: S. A. Pomeshkina, et al.
Published: (2015-01-01)

Effects of Pioglitazone and Irbesartan on Endothelial Dysfunction on Experimentally Streptozotocin-Induced Diabetic Nephropathy in Rats
by: Magdy I. Attallah, et al.
Published: (2018-07-01)

Diagnostic assessment of endothelial function in metabolic syndrome and coronary heart disease
by: V. A. Nevzorova, et al.
Published: (2011-04-01)

TYPE 2 DIABETES MELLITUS AND CORONARY HEART DISEASE
by: T. P. Bardymova, et al.
Published: (2017-02-01)

Endothelial dysfunction and prognosis after coronary interventions in patients with coronary heart disease and arterial hypertension
by: M. V. Kazak, et al.
Published: (2011-10-01)

APPLICATION OF BETARGIN IN THE TREATMENT OF STABLE CORONARY HEART DISEASE AND NON-ALCOHOLIC FATTY LIVER DISEASE
by: Manusha Yu. I., et al.
Published: (2018-11-01)

Pioglitazone abrogates testicular damage induced by testicular torsion/detorsion in rats
by: Nevertyty Mohamed Mahmoud, et al.
Published: (2019-08-01)

Endothelial dysfunction, nitric monooxide, and coronary heart disease
by: N A Mazur
Published: (2003-03-01)

Possibilities for correcting endothelial dysfunction in patients with arterial hypertension and coronary heart disease
by: E. V. Filippov
Published: (2019-04-01)

Effect of pioglitazone treatment in a patient with secondary multiple sclerosis
by: Pershadsingh Harrihar A, et al.
Published: (2004-04-01)

Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database
by: Sunghwan Suh, et al.
Published: (2015-06-01)

Pathophysiological importance of nitric oxide in coronary heart disease
by: Đorđević Vidosava B., et al.
Published: (2012-01-01)

Efficiency and Safety of Metformine and Pioglitazone in Patients with Coronary Heart Disease and Diabetes Mellitus Type 2
by: Z.A. Shaienko, et al.
Published: (2015-03-01)

Changes in Indicators of Oxidative Stress, Inflammation and Endothelial Dysfunction in Patients with Coronary Heart Disease during Lipid-Lowering Therapy
by: Julia A. Kotova, et al.
Published: (2019-09-01)

The role of asthma’s basic therapy in the development of endothelial dysfunction in children
by: Veronika M. Dudnyk, et al.
Published: (2015-02-01)

Epidemiological and pathogenetic paralels in patients with bronchial asthma in combination with coronary heart disease (review of the literature, observation of the authors)
by: N. A. Matsegora, et al.
Published: (2017-03-01)

Pioglitazone: A boon we know less about
by: Dilip Gude
Published: (2013-01-01)

Microparticles as Novel Biomarkers and Therapeutic Targets in Coronary Heart Disease
by: Bo-Da Zhou, et al.
Published: (2015-01-01)

Markers of Endothelial Damage, Inflammation, Oxidative and Cellular Stress in Patients with Coronary Artery Disease and Type 2 Diabetes
by: Julia A. Kotova, et al.
Published: (2020-06-01)

Structural-functional properties of the vascular wall in hypertensive patients with coronary heart disease: effects of felodipin and perindopril
by: Natal'ya Alekseevna Musikhina, et al.
Published: (2009-09-01)

Determination of Pioglitazone Hydrochloride in Tablets by High-Performance Liquid Chromatography
by: AMR Lotfy Saber
Published: (2008-12-01)

Usage of pioglitazone at Medanta, the Medicity
by: Ambrish Mithal, et al.
Published: (2014-01-01)

Anticonvulsant and ameliorative effects of pioglitazone on cognitive deficits, inflammation and apoptosis in the hippocampus of rat pups exposed to febrile seizure
by: Hussein Hussein, et al.
Published: (2019-03-01)

The Role of Endothelial Microparticle in Coronary Heart Disease as The Complications of Diabetes Mellitus
by: Eka Fithra Elfi, et al.
Published: (2019-05-01)

Pioglitazone: Indian perspective
by: Rishi Shukla, et al.
Published: (2011-01-01)

A retrospective study on finding correlation of pioglitazone and incidences of bladder cancer in the Indian population
by: V Balaji, et al.
Published: (2014-01-01)

Pioglitazone Improves Mitochondrial Organization and Bioenergetics in Down Syndrome Cells
by: Nunzia Mollo, et al.
Published: (2019-06-01)

Pioglitazone Attenuates Palmitate-Induced Inflammation and Endoplasmic Reticulum Stress in Pancreatic β-Cells
by: Seok-Woo Hong, et al.
Published: (2018-03-01)

Corrigendum: Pioglitazone Improves Mitochondrial Organization and Bioenergetics in Down Syndrome Cells
by: Nunzia Mollo, et al.
Published: (2020-07-01)

Clinical Course of Coronary Heart Disease Concomitant with Asthma
by: N. Y. Grigoryeva, et al.
Published: (2020-03-01)

Pioglitazone use and the risk of bladder cancer
by: Hsin-Wei Kuo, et al.
Published: (2014-02-01)

A study of the degree of inflammatory response of atherosclerotic plaque in the coronary artery in patients with impaired metabolism of homocysteine and vitamin D
by: O. S. Nykonenko, et al.
Published: (2020-12-01)

TRIMETAZIDINE MB ROLE IN THE OPTIMISATION OF THE ACUTE CORONARY SYNDROME TREATMENT: EFFECTS ON ENDOTHELIAL DYSFUNCTION AND SYSTEMIC INFLAMMATION
by: S. I. Davydov, et al.
Published: (2013-12-01)

Pioglitazone-Mediated Peroxisome Proliferator-Activated Receptor γ Activation Aggravates Murine Immune-Mediated Hepatitis
by: Rike Schulte, et al.
Published: (2020-04-01)

CORRELATION OF INFLAMMATION BIOMARKERS WITH THE TRADITIONAL RISK FACTORS IN PATIENTS WITH ACUTE CORONARY SYNDROME
by: I. S. Skopec, et al.
Published: (2016-05-01)

Biochemical markers of endothelial dysfunction in chronic obstructive pulmonary disease concurrent with hypertensive disease or coronary heart disease
by: A Kh Akhmineeva
Published: (2014-03-01)

Effect of anxiety and depression on endothelial function and inflammation degree of coronary heart disease patients with angina pectoris
by: Lin Ni, et al.
Published: (2016-01-01)